On 21st February 2017, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to CMD-003 for patients with R/R Lymphoma and Post-Transplant Lymphoproliferative Disease (PTLD) associated with Epstein Barr Virus (EBV).
Cell Medica’s CMD-003, also known as baltaleucel-T, is a preparation of autologous cytotoxic T-Cells, which have been programmed to target EBV antigens such as EBV Nuclear Antigen (EBVNA), BamHI-A Rightward Frame-1 (BARF1), and Latent Membrane Proteins 1 and 2 (LMP1, LMP2). CMD-003 has the potential to treat and manage a range of EVB associated malignancies such as lymphomas, gastric cancers, and nasopharyngeal carcinoma.
Current, active trials taking place with CMD-003 include the international, open-label, phase II CITADEL trial (NCT01948180), which aims to investigate the efficacy of the immunotherapy in EBV-positive Extranodal NK/T-Cell Lymphoma patients with aggressive disease. The estimated primary completion is December of this year. Moreover, the phase II, open-label, CIVIC trial (NCT02763254) aims to assess the safety and clinical activity of CMD-003 in patients with EBV-positive DLBCL, HL, and PTLD. However, primary results of this trial are not expected to be published until December 2018.
- Cell Medica: Lead Cancer Immunotherapy Candidate Receives FDA Fast Track Designation. 2017 Feb 21. http://www.businesswire.com/news/home/20170220005598/en/Cell-Medica-Lead-Cancer-Immunotherapy-Candidate-Receives. [Accessed 2017 Feb 21].
- National Cancer Institute. NCI Drug Dictionary – Baltaleucel-T. https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=783439. [Accessed 2017 Feb 21].
- Cell Medica. CMD-003. https://cellmedica.co.uk/products/oncology/cmd-003/. [Accessed 2017 Feb 21].